Patents Issued in June 6, 2019
-
Publication number: 20190167552Abstract: The disclosure relates to compositions and methods for treating keratin fibers. Compositions comprise part (A) comprising (a) at least one compound chosen from urea and urea derivatives; and part (B) comprising (b) at least one polyol compound. Methods comprise applying the composition to keratin fibers to provide long-lasting effects such as good curl definition and regularity, better movement and discipline, and/or good volume and frizz control. Kits comprising the composition are also disclosed.Type: ApplicationFiled: June 30, 2016Publication date: June 6, 2019Applicant: L'OREALInventors: Marina Tavares GREGOLIN, Ana Paula Leme DE MAGALHÃES, Manon CHAUMONTET, Sintia Aguiar MARTINS, Arthur Olimpio De Cunto CARVALHO
-
Publication number: 20190167553Abstract: Mixtures comprising a selected cooling active ingredient (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-propenamide and at least one other substance which acts as a solvent for (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-propenamide, wherein the substance is selected form the group consisting of benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethol, optamint, propylene glycol, further cooling active ingredients or mixtures thereof.Type: ApplicationFiled: August 9, 2016Publication date: June 6, 2019Inventors: Benoit JOIN, Michael BACKES, Arnold MACHINEK, Ulrike SIMCHEN, Jenny WEISSBRODT, Jens FAHLE
-
Publication number: 20190167554Abstract: The invention relates to aqueous, high active, self-preserving composition of mild surfactants which are used to create transparent liquid formulations with pH similar to skin's pH. More specifically, the composition comprise of sodium/potassium acyl isethionate of Formula I and mono potassium acyl glutamate of Formula II with solids content of at least 45% w/w, for personal care formulation that are ultra-mild, with skin pH and transparent.Type: ApplicationFiled: August 3, 2015Publication date: June 6, 2019Inventors: Arpit WANKHADE, Bhagyesh Jagannath SAWANT, Pritesh MHATRE, Nirmal KOSHTI, Pooja Vaidya KSHIRSAGAR, Ashwini BALLAL, Anuradha SHARMA, Kumar RAUNAK
-
Publication number: 20190167555Abstract: Oral care compositions including a hemostatic agent, wherein the hemostatic agent includes a mixture of oleanic acid and eugenol. Methods of making and using these compositions are also described.Type: ApplicationFiled: December 1, 2017Publication date: June 6, 2019Applicant: Colgate-Palmolive CompanyInventors: Shao Peng XU, Peng YAN, Ying YANG
-
Publication number: 20190167556Abstract: The invention relates to nail compositions including water, at least one high molecular weight latex comprising at least one styrene group, at least one latex lacking styrene groups, and at least one low molecular weight sulfopolyester compound, as well as to methods relating to application of such nail compositions.Type: ApplicationFiled: December 5, 2017Publication date: June 6, 2019Applicant: L'OréalInventors: I-Fan Hsieh, Christopher Michael MacNeill, XianZhi Zhou, Ramakrishnan Hariharan
-
Publication number: 20190167557Abstract: The present disclosure relates to a cosmetic composition for treatment of keratinous fibers, particularly for the temporary coloring of keratinous fibers, for example as a hair mascara or as a coloring agent for eyebrows. The composition contains water, at least one nonionic oil-in-water emulsifier, at least one hydrophobized pigment, polyphenylmethylsiloxane and at least one linear 1-alkanol with from about 14 to about 30 carbon atoms which is solid at 30° C., wherein the total amount of soap, relative to the weight of the cosmetic composition, is less than about 0.5 wt. % and particularly about 0 wt. %, and wherein the total amount of polysiloxanes, with the exception of polyphenylmethylsiloxane, relative to the weight of the cosmetic composition, is from about 0 to about 1 wt. % and particularly about 0 wt. %.Type: ApplicationFiled: December 4, 2018Publication date: June 6, 2019Applicant: Henkel AG & Co. KGaAInventors: Sabrina Jasmin Zirwen, Hartmut Manneck
-
Publication number: 20190167558Abstract: Formulations for oral care products that incorporate coconut oil for effectively removing bacteria from the mouth and methods for making these products are disclosed herein.Type: ApplicationFiled: November 30, 2018Publication date: June 6, 2019Inventors: Ginger Price, Martin Giniger
-
Publication number: 20190167559Abstract: The present invention relates to cosmetic anti-blemish compositions in gel form that are particularly useful in the lightening of shadows and in the reduction of bags under the eyes.Type: ApplicationFiled: May 24, 2017Publication date: June 6, 2019Inventors: Kassandra TADINI D'ANNOLFO, Priscila CAROLLO MONCAYO, Eduardo Alexandre DE OLIVEIRA REIS, Fabiana PAES, Ricardo Augusto SANTOS DE OLIVEIRA, Daniela ZIMBARDI
-
Publication number: 20190167560Abstract: A method for treating a person's skin is disclosed. The method includes topically applying to the skin a composition comprising from 0.001% to 20% by weight of an aqueous, alcoholic, or aqueous-alcoholic extract from Tetracentron sinense, wherein the extract from Tetracentron sinense reduces oxidation in the skin or reduces MMP-1 activity in the skin.Type: ApplicationFiled: December 27, 2018Publication date: June 6, 2019Inventors: Tiffany CARLE, David GAN, Michelle HINES
-
Publication number: 20190167561Abstract: This disclosure relates to methods of reducing or inhibiting the graying of hair by topically applying various cosmetic formulations to hair follicles and/or to the skin overlying hair follicles. The formulations applied in these methods include green tea extract and one or more additional plant extracts, in addition to one or more cosmetically acceptable carriers and/or accessory ingredients.Type: ApplicationFiled: August 11, 2017Publication date: June 6, 2019Inventors: Ana Paula Pedroso Oliveira, Gabriela Placoná Diniz, Juliana Carvalhães Lago, Kelen Fabiola Arroteia, David E. Fisher
-
Publication number: 20190167562Abstract: The present invention provides a probiotic-containing animal shampoo and methods of using a probiotic-containing animal shampoo for cleansing, conditioning and deodorizing an animal's fur or hair and for supporting digestive health in the animal after the animal orally ingests the probiotic deposited by the shampoo during the animal's oral self-grooming of its fur or hair. The methods of the invention are particularly useful for administering probiotics to an animal, preferably a dog.Type: ApplicationFiled: October 29, 2018Publication date: June 6, 2019Inventor: Shawn E. Seitz
-
Publication number: 20190167563Abstract: Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.Type: ApplicationFiled: February 4, 2019Publication date: June 6, 2019Applicant: BASF SEInventors: Andreas Reindl, Rolf Knöll, Christine Lang, Markus Veen, Eckhard Budde, Mewes Boettner
-
Publication number: 20190167564Abstract: Disclosed is a topical skin care formulation comprising water, kaolin, glycerin, lactobacillus ferment, Helianthus annuus seed extract, and Terminalia ferdinandiana fruit extract.Type: ApplicationFiled: February 5, 2019Publication date: June 6, 2019Inventors: David GAN, Patricia JACOBY
-
Publication number: 20190167565Abstract: The present invention teaches compositions, methods and kits for treating skin conditions, including dandruff. In various embodiments, the compositions include an effective amount of one or more probiotic microorganism of vaginal origin and/or a fraction thereof and/or a component of the metabolome for preventing and/or treating skin disorders of the scalp.Type: ApplicationFiled: February 8, 2019Publication date: June 6, 2019Inventors: Marc M. Baum, Janelle M. Baum
-
Publication number: 20190167566Abstract: The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient.Type: ApplicationFiled: February 5, 2019Publication date: June 6, 2019Inventors: Stuart D. SHANLER, Christopher POWALA
-
Publication number: 20190167567Abstract: The present invention relates generally to compositions and methods of using the same.Type: ApplicationFiled: February 5, 2019Publication date: June 6, 2019Inventors: Ryan Doxey, Adam Sabouni, Eleftherios Kougoulos, Nathan Stasko
-
Publication number: 20190167568Abstract: [PROBLEMS TO BE SOLVED] To provide a method of advantageously improving a transdermal permeation amount of a steroid drug to diseased portions when treating ophthalmic diseases such as chalazion, blepharitis, allergic conjunctivitis, vernal keratoconjunctivitis, and meibomian gland dysfunction. [SOLUTION] To provide the transdermal drug delivery system for administering a drug via the eyelid skins that have been treated with a microneedle array, featured in that the drug is a water-soluble steroid, and the transdermal drug delivery system is a water-containing base adhesive skin patch.Type: ApplicationFiled: June 29, 2017Publication date: June 6, 2019Applicants: SENJU USA, INC., NICHIBAN CO., LTD.Inventors: Takahiro OGAWA, Akiharu ISOWAKI, Tetsuo KIDA, Koji KAWAHARA, Emiko TESHIMA, Teppei OSAKO
-
Publication number: 20190167569Abstract: Shortcomings in the transdermal delivery of an herbal extraction are overcome by using an aqueous extraction of a saponin plant to enhance herbal extraction from a subject plant and to enhance transdermal delivery of a composition including the herbal extraction. In one embodiment, a composition for transdermal delivery comprises an herbal extract solution having soluble components of a subject plant solvated in an extraction medium. The extraction medium includes soluble components of a saponin plant solvated in water, and the saponin plant and the subject plant are different plants or types of plants. Products including the composition for transdermal delivery, and methods of preparing and using the composition are also described.Type: ApplicationFiled: June 30, 2017Publication date: June 6, 2019Inventor: Nuri Murat ÖZAYMAN
-
Publication number: 20190167570Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours.Type: ApplicationFiled: February 6, 2019Publication date: June 6, 2019Applicant: Revogenex Ireland LtdInventors: Lucy Lu, Scott Reines, Jeffrey Ping
-
Publication number: 20190167571Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours.Type: ApplicationFiled: February 6, 2019Publication date: June 6, 2019Applicant: Revogenex Ireland LtdInventors: Lucy Lu, Scott Reines, Jeffrey Ping
-
Publication number: 20190167572Abstract: A capsule device, which can induce vascular bed formation and formation of a space for cell transplantation in subcutaneous tissue in which the device is implanted, is provided. A sustained drug release capsule device, which is to be subcutaneously implanted for subcutaneous sustained release of an angiogenesis-inducing factor as well as formation of a vascular bed as a basis for cell transplantation and a space for cell transplantation in cell therapy, the capsule being made of a material which is not soluble in a biological body and does not adhere to a biological body, and having micropores for sustained release of the angiogenesis-inducing factor.Type: ApplicationFiled: November 7, 2016Publication date: June 6, 2019Applicant: TOHOKU UNIVERSITYInventors: Toshiaki ABE, Nobuhiro NAGAI, Shinji YAMADA, Masafumi GOTO, Kozue IMURA, Hirokazu KAJI
-
Publication number: 20190167573Abstract: Certain embodiments of the invention include medical materials and methods comprising a biodegradable hydrophilic hydrogel comprising dispersed lipophilic particles that comprise a therapeutic agent, wherein the lipophilic particles have a low water solubility in physiological saline at physiological temperature.Type: ApplicationFiled: November 29, 2018Publication date: June 6, 2019Inventors: Peter Jarrett, Rami El-Hayek, Amarpreet S. Sawhney, Sarah Guedez
-
Publication number: 20190167574Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.Type: ApplicationFiled: December 6, 2018Publication date: June 6, 2019Inventors: Hui Rong Shen, Na Gan
-
Publication number: 20190167575Abstract: A flexible implantable contraceptive disc device can be inserted inside the female body. The circular device can be bent and inserted into a laparoscopy tube, which allows it to be delivered to the appropriate location inside a female subject. The disc has three layers, a central core silicon reservoir containing the active ingredient, such as a contraceptive, which is sandwiched and encased by upper and lower porous silicon casings. The casings are porous to the contraceptive, allowing controlled release over a prolonged period of time. The lower casing has a series of micro-hooks around the circumference, allowing the disc device to be attached to a desired tissue by rotating the disc such that the hooks engage with the tissue. Such a device is easier to insert, and to remove, than the rod-like rigid plastic T-shape IUDs which are considerably larger and more expensive to manufacture.Type: ApplicationFiled: August 21, 2017Publication date: June 6, 2019Inventors: Mehmet Rafet GAZVANI, Halil Ibrahim TEKIN
-
Publication number: 20190167576Abstract: An anchor molecule is provided that (1) binds monoclonal antibody products with high affinity and (2) is anchored in a biologic tissue of interest. Therapeutic antibodies can either be delivered to the biologic tissue before, during, or after the delivery of the anchor molecule. Because the present invention binds monoclonal antibody products and is anchored in a biologic tissue, the result is that monoclonal antibody products are also anchored in a biologic tissue.Type: ApplicationFiled: September 6, 2017Publication date: June 6, 2019Inventor: Ira Hyman Schachar
-
Publication number: 20190167577Abstract: A method and kit for the sequential early introduction to an infant of at least two allergens to decrease the infant's risk for developing allergies, the method involving administering an initial lower, exposure dose of a first allergen for a day or two, followed by administering a higher maintenance dose of the first allergen for several days, followed by administering the maintenance dose of the first allergen and an initial lower, exposure dose of a second allergen for a day or two, followed by administering the higher maintenance dose of the first allergen and a higher maintenance does of the second allergen for several days. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula or to mother's milk. Alternatively, the allergens can already be provided in baby formula, or in other foods such as snack bars, cookies, or gels.Type: ApplicationFiled: November 21, 2018Publication date: June 6, 2019Inventors: Andrew Leitner, Katie Marks, Aaron Rowe, Daniel Zakowski
-
Publication number: 20190167578Abstract: The present invention generally optimizes the means and effects of ingesting terpene compounds. As such, the intended effects on the user vary by compound formulation; while the specific process of consumption, and the formulations of the compounds themselves are proprietary. Currently, most of these terpene compounds are known, and consumed in various amounts and combinations as food flavorings; the present invention however, focuses the effects of these compounds to synergize with those of medical cannabis. Furthermore, due to the route of transmucosal administration of these terpene strips, the present invention expedites, optimizes, and elevates both the effects of Medical Cannabis and Industrial Hemp.Type: ApplicationFiled: November 16, 2018Publication date: June 6, 2019Inventor: Daniel Carew Sanders
-
Publication number: 20190167579Abstract: In one aspect, a dry powder comprising respirable dry particles that comprise amorphous itraconazole in an amount of about 45% to about 75%, sodium sulfate in an amount of about 10% to about 55%, and optionally one or more other excipients, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. In another aspect, a dry powder comprising respirable dry particles that comprise amorphous itraconazole in an amount of about 45% to about 55%, sodium chloride in an amount of about 30% to about 40%, and leucine in an amount of about 10% to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.Type: ApplicationFiled: October 29, 2018Publication date: June 6, 2019Inventors: Jason M. Perry, Jean C. Sung, David L. Hava
-
Publication number: 20190167580Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.Type: ApplicationFiled: February 4, 2019Publication date: June 6, 2019Inventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
-
Publication number: 20190167581Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: ApplicationFiled: January 4, 2019Publication date: June 6, 2019Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Publication number: 20190167582Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.Type: ApplicationFiled: February 4, 2019Publication date: June 6, 2019Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
-
Publication number: 20190167583Abstract: The present invention relates to a cannabinoid containing oral solution. Preferably the oral solution comprises a cannabinoid, a lipid solvent, a sweetener and ethanol, characterised in that the sweetener is an ultrahigh potency sweetener.Type: ApplicationFiled: June 29, 2017Publication date: June 6, 2019Inventor: Harshit Shah
-
Publication number: 20190167584Abstract: The subject matter of this invention relates to block copolymers (BCPs) and, more particularly, to block copolymers capable of self-assembly into nanoparticles for the delivery of hydrophobic cargos. The BCPs include a hydrophobic block that contains a thioether functional group that is susceptible to oxidation, transforming the solubility of the block from hydrophobic to hydrophilic, thereby releasing the hydrophobic cargo of the nanoparticle.Type: ApplicationFiled: December 5, 2017Publication date: June 6, 2019Inventors: Dylan Boday, Willy Chin, Mareva B. Fevre, Jeannette Garcia, James L. Hedrick, Eunice Leong, Nathaniel H. Park, Rudy J. Wojtecki, Yi Yan Yang
-
Publication number: 20190167585Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.Type: ApplicationFiled: January 11, 2019Publication date: June 6, 2019Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard, Muhammed Majeed
-
Publication number: 20190167586Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: July 13, 2018Publication date: June 6, 2019Inventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20190167587Abstract: Provided herein is a method for treating a pulmonary disease using mesenchymal stem cell-derived artificial nanosomes exhibiting a significantly excellent capability to regenerate alveoli compared to mesenchymal stem cells themselves and natural exosomes derived from human adipose-derived mesenchymal stem cells, wherein the mesenchymal stem cell-derived artificial nanosomes of the present disclosure may be collected through a simple production method using an extruder and an ultracentrifuge, instead of treating mesenchymal stem cells with a separate chemical substance and the potential side effects caused by stem cell therapeutic agents is low.Type: ApplicationFiled: November 30, 2018Publication date: June 6, 2019Applicant: MDIMUNE INC.Inventors: Shin Gyu BAE, Yeon-Mok OH
-
Publication number: 20190167588Abstract: The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.Type: ApplicationFiled: June 30, 2016Publication date: June 6, 2019Applicant: Sequessome Technology Holdings LimitedInventors: William HENRY, Richard Wolf GARRAWAY
-
Publication number: 20190167589Abstract: Disclosed are biomimetic proteolipid nanovesicles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. In particular embodiments, drug delivery vehicles are provided composed of synthetic phospholipids and cholesterol, enriched of leukocyte membranes, and surrounding an aqueous core. These nanovesicles are able to both avoid the immune system, thanks to the presence on their surface of self-tolerance proteins, as CD-45, CD-47, and MHC-1, and target inflamed endothelium, thereby diffusing in the tumor microenvironment. These properties make the composition highly suited for targeted drug delivery to mammalian tumor cells in vitro and in situ.Type: ApplicationFiled: August 22, 2018Publication date: June 6, 2019Inventors: Ennio Tasciotti, Roberto Molinaro
-
Publication number: 20190167590Abstract: Novel compositions, formulations and dosage forms comprising stabilized micronized opioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts. Stabilized micronized opioid particles having a DV90 particle size distribution of less and or equal to 10? or less than or equal to 20? are disclosed. Methods for micronizing an opioid to provide stabilized micronized opioid particles are also disclosed.Type: ApplicationFiled: September 26, 2018Publication date: June 6, 2019Inventors: Michael Zamloot, Cherng-Chyi Fu, De-Hwa Chao, Andrei Blasko, Su Il Yum
-
Publication number: 20190167591Abstract: Disclosed are taste-masked pharmaceutical formulations of raltegravir comprising coated API granules mixed with a screened powder excipient blend in either tablet or sachet form. The core and coated granules are produced using a Wurster process for enhanced control of particle size. Also disclosed are methods of treating HIV, e.g., in pediatric populations.Type: ApplicationFiled: December 14, 2018Publication date: June 6, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Karen Cassidy Thompson, Kimberly Nicole Kaighn, Indra Neil Mukherjee, Catherine Elizabeth Diimmler, Hedy Teppler Weiser, Christopher Mancinelli
-
Publication number: 20190167592Abstract: The present invention provides a process for manufacturing a co-processed directly compressible excipient for sustained/extended release formulation based on pharmaceutically acceptable inert diluent, hydrophilic swellable polymer and a binder.Type: ApplicationFiled: July 5, 2017Publication date: June 6, 2019Inventors: Anil K. Jain, Rajan KALE
-
Publication number: 20190167593Abstract: A cyclohexene derivative or pharmaceutically acceptable salt thereof and application thereof, which belongs to the technical field of pharmaceutical technology is provided. The cyclohexene derivative of formula I or pharmaceutically acceptable salt thereof is a new broad-spectrum anti-influenza compound, having a great inhibiting effect on influenza viruses, specifically, it has a high activity to virus strains which is drug-resistant to Oseltamivir, and may be used as a broad-spectrum anti-influenza NA inhibitor effective to Tamiflu drug-resistance, for treating the flu caused by influenza viruses, thereby it is a broad-spectrum anti-influenza drug.Type: ApplicationFiled: April 27, 2017Publication date: June 6, 2019Inventors: Jiancun Zhang, Deyao Li, Hong Li, Kun Wang, Yan Liu, Yan Wu, Xing Tang, Jianbo Song
-
Publication number: 20190167594Abstract: The present invention relates to means for protecting bioactive materials in mammalian food or feed formulations used to enhance the health status of mammals.Type: ApplicationFiled: October 29, 2018Publication date: June 6, 2019Inventors: Amir Barzilay, Hagit Koren-Lichtig
-
Publication number: 20190167595Abstract: In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the group consisting of copper iodide, copper chloride, copper bromide, copper sulfate, copper formate, or combinations thereof.Type: ApplicationFiled: October 25, 2018Publication date: June 6, 2019Applicant: Otsuka Pharmaceutical Co., Ltd.Inventors: Mark ZDEBLICK, Markus CHRISTEN, Nikhil PARGAONKAR, Nikolaus LEIST, Kurt SCHEINPFLUG, Patricia JOHNSON, Benedict COSTELLO
-
Publication number: 20190167596Abstract: The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.Type: ApplicationFiled: July 28, 2017Publication date: June 6, 2019Inventors: Anna Nardi Ricart, Josep María Suñé Negre, Núria Reig Bolaño, Raúl Insa Boronat, Oscar Huertas Gambín, Santiago Esteva Gras, Gal·la Pericot Mohr
-
Publication number: 20190167597Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.Type: ApplicationFiled: December 28, 2018Publication date: June 6, 2019Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
-
Publication number: 20190167598Abstract: The invention relates to an improved tetrahydrobiopterin formulation for treating patients affected by hyperphenylalaninemia. More specifically, the formulation of the invention permits a prolonged residence of tetrahydrobiopterin in the plasma, and/or a higher concentration of sapropterin in the plasma, enabling notably the treatment of HPA patients that would usually not be classified as responders to tetrahydrobiopterin loading test, and therefore left without any pharmacological treatment opportunity, but only with a strictly controlled protein diet.Type: ApplicationFiled: July 27, 2017Publication date: June 6, 2019Inventors: Gilles PAIN, Fabio CANNATA, Bareket GELBHART
-
Publication number: 20190167599Abstract: Shelf life of soft gelatin capsules comprising a soft gelatin shell encapsulating a pharmaceutical formulation comprising cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount from 25 wt % to 99 wt % of the formulation and cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount from 1 wt % to 75 wt % of the formulation in which the gelatin component of the shell is Type B gelatin, is improved by replacing up to 75 wt % of the gelatin component with porcine Type A gelatin.Type: ApplicationFiled: January 24, 2019Publication date: June 6, 2019Applicant: Chrysalis Pharma AGInventor: Johannes SPLEISS
-
Publication number: 20190167600Abstract: The present invention provides a way to capture a biomolecule such as a protein in one or more layers of covalently bonded amorphous silica, forming a cage or shell which preserves the shape of the protein and prevents denaturation caused by heat and/or aging and/or non-physiological conditions, through unfolding and loss of secondary and/or higher order structure.Type: ApplicationFiled: August 3, 2017Publication date: June 6, 2019Applicant: UNIVERSITY OF BATHInventors: Asel Sartbaeva, Stephen Wells
-
Publication number: 20190167601Abstract: In one or more embodiments the present invention provides a three layer bimodal amphiphilic co-network (?-APCN) based drug delivery device and methods for its making and use. In various embodiments, the system is based on a three-layer scheme. A center layer is composed of a ?-APCN matrix containing a high drug loading and exhibiting high drug diffusivity and two outer layers which are also ?-APCN-based, contain no-drug and are instead loaded with a diffusional barrier such as vitamin E, which considerably slows drug diffusion through these outer layers. Both modeling and experimental data demonstrates that the combined effect of non-uniform distribution of drug loading and diffusion constants within the three-layer systems of various embodiments of the present invention is capable of maintaining a low local drug concentration at the polymer-fluid interface, thus achieving zero-order kinetics.Type: ApplicationFiled: April 24, 2017Publication date: June 6, 2019Applicant: The University of AkronInventors: Mukerrem CAKMAK, Gustavo Andres GUZMAN CARDOZO, Faruk ORGE, Turgut NUGAY
